Company registration number 07928078 (England and Wales)
PRINCIPAL FORENSIC TOXICOLOGY AND DRUGS CONSULTANCY LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2024
PAGES FOR FILING WITH REGISTRAR
PRINCIPAL FORENSIC TOXICOLOGY AND DRUGS CONSULTANCY LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 4
PRINCIPAL FORENSIC TOXICOLOGY AND DRUGS CONSULTANCY LTD (REGISTERED NUMBER: 07928078)
BALANCE SHEET
AS AT 31 JANUARY 2024
31 January 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
1,617
1
Current assets
Debtors
4
10,470
12,060
Cash at bank and in hand
72,503
64,642
82,973
76,702
Creditors: amounts falling due within one year
5
(13,777)
(13,592)
Net current assets
69,196
63,110
Net assets
70,813
63,111
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
70,713
63,011
Total equity
70,813
63,111

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 January 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 9 September 2024 and are signed on its behalf by:
Mrs E A Scott-Ham
Director
PRINCIPAL FORENSIC TOXICOLOGY AND DRUGS CONSULTANCY LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2024
- 2 -
1
Accounting policies
Company information

Principal Forensic Toxicology And Drugs Consultancy Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 10 Upper Grosvenor Road, Tunbridge Wells, England, TN1 2EP.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for consultancy services provided in the normal course of business, and is shown net of VAT. Income is recognised at the invoice date.

 

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computer equipment
33% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

1.5
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

PRINCIPAL FORENSIC TOXICOLOGY AND DRUGS CONSULTANCY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2024
- 3 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
2
2
3
Tangible fixed assets
Computer equipment
£
Cost
At 1 February 2023
2,627
Additions
1,662
At 31 January 2024
4,289
Depreciation and impairment
At 1 February 2023
2,626
Depreciation charged in the year
46
At 31 January 2024
2,672
Carrying amount
At 31 January 2024
1,617
At 31 January 2023
1
4
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
10,470
12,060
PRINCIPAL FORENSIC TOXICOLOGY AND DRUGS CONSULTANCY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2024
- 4 -
5
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
227
199
Taxation and social security
9,145
10,350
Other creditors
4,405
3,043
13,777
13,592
2024-01-312023-02-01false09 September 2024CCH SoftwareCCH Accounts Production 2024.200No description of principal activityM Scott-HamMrs E A Scott-Hamfalsefalse079280782023-02-012024-01-31079280782024-01-31079280782023-01-3107928078core:ComputerEquipment2024-01-3107928078core:ComputerEquipment2023-01-3107928078core:CurrentFinancialInstrumentscore:WithinOneYear2024-01-3107928078core:CurrentFinancialInstrumentscore:WithinOneYear2023-01-3107928078core:CurrentFinancialInstruments2024-01-3107928078core:CurrentFinancialInstruments2023-01-3107928078core:ShareCapital2024-01-3107928078core:ShareCapital2023-01-3107928078core:RetainedEarningsAccumulatedLosses2024-01-3107928078core:RetainedEarningsAccumulatedLosses2023-01-3107928078bus:Director22023-02-012024-01-3107928078core:ComputerEquipment2023-02-012024-01-31079280782022-02-012023-01-3107928078core:ComputerEquipment2023-01-3107928078bus:PrivateLimitedCompanyLtd2023-02-012024-01-3107928078bus:SmallCompaniesRegimeForAccounts2023-02-012024-01-3107928078bus:FRS1022023-02-012024-01-3107928078bus:AuditExemptWithAccountantsReport2023-02-012024-01-3107928078bus:Director12023-02-012024-01-3107928078bus:FullAccounts2023-02-012024-01-31xbrli:purexbrli:sharesiso4217:GBP